Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11485630rdf:typepubmed:Citationlld:pubmed
pubmed-article:11485630lifeskim:mentionsumls-concept:C0001483lld:lifeskim
pubmed-article:11485630lifeskim:mentionsumls-concept:C0040669lld:lifeskim
pubmed-article:11485630lifeskim:mentionsumls-concept:C0237401lld:lifeskim
pubmed-article:11485630lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:11485630lifeskim:mentionsumls-concept:C0010674lld:lifeskim
pubmed-article:11485630lifeskim:mentionsumls-concept:C0014609lld:lifeskim
pubmed-article:11485630lifeskim:mentionsumls-concept:C0458827lld:lifeskim
pubmed-article:11485630lifeskim:mentionsumls-concept:C0013682lld:lifeskim
pubmed-article:11485630lifeskim:mentionsumls-concept:C1112870lld:lifeskim
pubmed-article:11485630lifeskim:mentionsumls-concept:C1522010lld:lifeskim
pubmed-article:11485630pubmed:issue11lld:pubmed
pubmed-article:11485630pubmed:dateCreated2001-8-3lld:pubmed
pubmed-article:11485630pubmed:abstractTextA phase I clinical trial was conducted in which recombinant adenovirus containing the cystic fibrosis trans-membrane regulator (CFTR) (Ad2/CFTR) was administered by bronchoscopic instillation or aerosolization to the lungs of cystic fibrosis (CF) patients. In this paper, we evaluate the efficiency of Ad2/CFTR-mediated transduction of bronchial airway cells. The ability of an Ad2/CFTR vector to transduce airway cells was first evaluated in patients to whom the vector was administered by bronchoscopic instillation. Cells at the administration site were collected 2 days after treatment by bronchoscopic brushing. Ad2-specific CFTR DNA was detected in four of five individuals by PCR, and Ad2-specific CFTR RNA was detected in three of five individuals by RT-PCR. Ad2/CFTR-mediated transduction of airway epithelial cells was then determined in CF individuals receiving this vector by aerosol inhalation. Ad2-specific CFTR DNA was detected in 13 of 13 individuals 2 days after aerosolization, and in 3 of 5 individuals 7 days after aerosolization. Ad2-specific RNA was detected in 4 of 13 individuals on day 2, but was not detected in the 5 individuals tested on day 7. The percentage of airway epithelial cells containing nuclear-localized vector DNA was < or =2.4% as determined by fluorescence in situ hybridization (FISH). However, in some cases, a high percentage of nonepithelial mononuclear cells or squamous metaplastic epithelial cells was infected with the adenoviral vector. In conclusion, aerosol administration is a feasible means to distribute adenoviral vectors throughout the conducting airways, but improvements in adenovirus-mediated transduction of airway epithelial cells are necessary before gene therapy for CF will be effective.lld:pubmed
pubmed-article:11485630pubmed:languageenglld:pubmed
pubmed-article:11485630pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11485630pubmed:citationSubsetIMlld:pubmed
pubmed-article:11485630pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11485630pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11485630pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11485630pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11485630pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11485630pubmed:statusMEDLINElld:pubmed
pubmed-article:11485630pubmed:monthJullld:pubmed
pubmed-article:11485630pubmed:issn1043-0342lld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:SmithA EAElld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:MorrisJ EJElld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:PavelkaKKlld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:WadsworthS...lld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:DorkinHHlld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:JosephP MPMlld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:O'SullivanB...lld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:PerriconeM...lld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:BalfourRRlld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:MeekerD PDPlld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:LapeyAAlld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:St GeorgeJ...lld:pubmed
pubmed-article:11485630pubmed:authorpubmed-author:PlogM SMSlld:pubmed
pubmed-article:11485630pubmed:issnTypePrintlld:pubmed
pubmed-article:11485630pubmed:day20lld:pubmed
pubmed-article:11485630pubmed:volume12lld:pubmed
pubmed-article:11485630pubmed:ownerNLMlld:pubmed
pubmed-article:11485630pubmed:authorsCompleteYlld:pubmed
pubmed-article:11485630pubmed:pagination1383-94lld:pubmed
pubmed-article:11485630pubmed:dateRevised2006-4-21lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:meshHeadingpubmed-meshheading:11485630...lld:pubmed
pubmed-article:11485630pubmed:year2001lld:pubmed
pubmed-article:11485630pubmed:articleTitleAerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium.lld:pubmed
pubmed-article:11485630pubmed:affiliationGenzyme Corporation, Framingham, MA 01701, USA. michael. perricone@genyme.comlld:pubmed
pubmed-article:11485630pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11485630pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11485630pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:11485630pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11485630lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11485630lld:pubmed